||Awaiting HTA submission from Applicant
||As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of teclistamab compared with the current standard of care.
|Full pharmacoeconomic assessment commissioned by HSE
|Pre-submission consultation with Applicant